Sign up to all DiabetesontheNet journals
Journals
Sign up to all DiabetesontheNet journals
By clicking ‘Subscribe’, you are agreeing that DiabetesontheNet.com are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.
Are you a healthcare professional? This website is for healthcare professionals only. To continue, please confirm that you are a healthcare professional below.
We use cookies responsibly to ensure that we give you the best experience on our website. If you continue without changing your browser settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies.
Journal of
Diabetes Nursing
Issue:
Early View
Tirzepatide to be available in prefilled injection pen
Eli Lilly has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has become the first major regulator to issue marketing authorisation for tirzepatide solution for injection in an alternative KwikPen presentation. It will be available through prescription in Great Britain for two indications:
Tirzepatide (sold as Mounjaro) is a once-weekly GIP analogue combined with a GLP-1 analogue. It works by activating both GIP and GLP-1 receptors to promote the secretion of incretin hormones that increase the production of insulin and decrease the glucose produced by the liver, lowering blood glucose.
It has previously received marketing authorisation for these indications in different presentations. The Mounjaro KwikPen will, however, deliver four doses, rather than the one dose from the previously approved Mounjaro pen. It is hoped that presenting a month’s treatment in one pen will allow for convenient use.
The most common side effects are nausea, diarrhoea, vomiting and constipation. Hypoglycaemia is very common in people with diabetes when used with a sulfonylurea or insulin. Women with obesity or overweight using oral contraceptives should consider also using a barrier method of contraception or switching to a non-oral contraceptive method.
With nearly one in three adults being obese, demand for the drug is expected to be high. When supplies become available in the coming weeks, healthcare professionals are being asked to ensure that all prescribing is within the authorised indications.
Improving care for people experiencing homelessness with diabetes
Prevention of diabetic maculopathy: Trial of oral medication begins
Analysis reveals extent of undiagnosed type 2 diabetes
Assessing self-efficacy among Jordanians with type 1 diabetes
Diabetes prehabilitation programme
Novel antidiabetes drugs improve composite renal outcomes
Standardising a pathway for the first year of care for children and young people diagnosed with type 2 diabetes
Helping homeless adults to overcome the challenges of managing their condition.
16 Apr 2024
Man becomes world’s first recipient of trial drug for diabetic sight loss.
12 Apr 2024
Scale of undiagnosed type 2 diabetes and prediabetes in England revealed in new research.
3 Apr 2024
How belief in ability to perform self-care practices affects healthy behaviours.
3 Apr 2024